What Dxome does

Dxome Co., Ltd. (주)디엑솜 is a privately held South Korean diagnostics company headquartered in Seongnam-si, Gyeonggi-do, operating in the genomic and liquid biopsy testing segment. The company offers two core product lines: DxSeq, a germline genomic DNA sequencing platform designed to detect hereditary mutations for proactive health management, and DxLiquid, a liquid biopsy platform that analyzes circulating tumor DNA (ctDNA) to identify somatic mutations supporting cancer treatment selection, response monitoring, and recurrence detection. Together, the two products are positioned to cover the cancer care continuum from hereditary risk assessment through treatment monitoring.

Dxome distributes its diagnostic products through a direct sales motion targeting healthcare institutions, laboratories, and medical professionals, with its primary market in South Korea. The company pursues international expansion through active participation in medical and laboratory conferences across Asia, Europe (MEDICA in Germany), and the Middle East (World Health Expo Labs Dubai), including events such as the ELSI Rare Disease Diagnosis Symposium, Laboratory Medicine Congress & Exhibition, American Society of Human Genetics, and American Spatial Biology Congress. Its go-to-market appears event-driven, aimed at building awareness among healthcare professionals and institutional buyers rather than consumer marketing.

The business model is anchored in diagnostic product sales, though no pricing model, revenue mechanics, customer count, or financial performance figures are publicly disclosed. No funding rounds, headcount, management team bios, patents, certifications, or regulatory approvals appear in available sources, limiting transparency. Operationally the company is active — exhibiting at conferences through early 2026 — but quantitative scale and growth signals are not disclosed.

Name

Dxome

Legal name

Dxome Co., Ltd.

Website

https://dxome.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Dxome is a privately held South Korean diagnostics company offering DxSeq germline DNA sequencing and DxLiquid ctDNA liquid biopsy platforms for hereditary mutation detection and cancer care, selling directly to healthcare providers and laboratories.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

Keywords

• Genomic diagnostics
• Liquid biopsy
• Germline testing
• Cancer diagnostics
• Hereditary mutation detection

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels1 record

Core offering

Dxome develops and sells molecular diagnostic products (screening panels and detection kits) centered on two proprietary platforms: DxSeq, which analyzes genomic DNA to detect hereditary mutations, and DxLiquid, which analyzes circulating tumor DNA (ctDNA) to identify somatic mutations for cancer treatment selection, response monitoring, and recurrence detection. Together these products serve healthcare providers and individuals across hereditary disease risk assessment and the full cancer care continuum.

Product overview

Dxome offers a unified portfolio of genomic and liquid biopsy diagnostic solutions. The core products include DxSeq for germline genetic testing (analyzing hereditary mutations from genomic DNA) and DxLiquid for somatic mutation detection through liquid biopsy technology (analyzing circulating tumor DNA). Together, these products support the complete cancer care continuum from risk assessment and early detection through treatment selection and monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• DxSeq: Advanced germline solutions that analyze genomic DNA to detect hereditary mutations, empowering proactive health management for individuals and their families.
• DxLiquid

Products and services

• DxSeq Advanced germline diagnostic solution that analyzes genomic DNA to detect hereditary mutations, empowering proactive health management for individuals and their families. Targeted at healthcare institutions and laboratories offering hereditary genetic testing.
• DxLiquid Cutting-edge liquid biopsy product that analyzes circulating tumor DNA (ctDNA) to identify somatic mutations, aiding in cancer treatment selection, response monitoring, and recurrence detection for optimal cancer care. Targeted at oncology laboratories, hospitals, and cancer treatment centers.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Geninus: Geninus is a Korean molecular diagnostics company specializing in NGS-based cancer panels and ctDNA testing, closely overlapping with DxLiquid's somatic mutation focus.
• Natera: Natera operates Signatera and other ctDNA-based liquid biopsy assays for oncology monitoring and recurrence detection — a near-direct functional overlap with DxLiquid.
• Tempus: Tempus provides NGS-based molecular profiling and liquid biopsy for oncology treatment selection, a core overlapping capability with Dxome's DxLiquid and DxSeq portfolio.
• Guardant Health: Guardant Health is a global leader in liquid biopsy and ctDNA-based oncology testing (e.g., Guardant360), making it the closest direct peer to Dxome's DxLiquid offering.

Broad incumbents

• Foundation Medicine (Roche): Foundation Medicine offers NGS-based comprehensive genomic profiling for solid tumors and hematologic malignancies, directly competing with DxLiquid and serving biopharma companion diagnostic needs that DxSeq+DxLiquid also target.
• NeoGenomics: NeoGenomics provides oncology-focused molecular and genetic testing services across solid tumors and hematologic malignancies, broadly overlapping with Dxome's cancer diagnostic menu.

Regional players

• Macrogen: Macrogen is a Korean-headquartered genomic sequencing services and diagnostics provider; it is the most relevant domestic Korean peer to Dxome across germline and NGS-based testing.

Emerging players

• Personalis: Personalis offers ultra-sensitive NGS-based cancer genomics, including ctDNA assays (NeXT Personal), placing it in the same emerging high-sensitivity liquid biopsy category as DxLiquid.
• Sengenics: Sengenics provides protein and genomics-based functional diagnostics, including cancer and rare disease panels — overlapping with DxSeq's hereditary and rare-disease positioning.
• Celemics: Celemics is a Korean NGS target enrichment and molecular diagnostics company serving clinical and research labs; its genomic assay offerings overlap with Dxome's sequencing-based products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/dxome

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dxome